Genmab A/S (GMAB) Competitors

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Do insiders & institutionals have more ownership in GMAB or TAK?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the media favor GMAB or TAK?

In the previous week, Genmab A/S had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 3 mentions for Genmab A/S and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.67 beat Genmab A/S's score of 0.00 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GMAB or TAK more profitable?

Genmab A/S has a net margin of 35.11% compared to Takeda Pharmaceutical's net margin of 2.36%. Genmab A/S's return on equity of 18.08% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	35.11%	18.08%	14.52%
Takeda Pharmaceutical	2.36%	10.64%	5.14%

Which has more risk & volatility, GMAB or TAK?

Genmab A/S has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.

Which has better earnings and valuation, GMAB or TAK?

Genmab A/S has higher earnings, but lower revenue than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.19	$1.14B	$1.76	11.60
Takeda Pharmaceutical	$30.09B	1.64	$712.33M	$0.22	70.68

Do analysts rate GMAB or TAK?

Genmab A/S currently has a consensus price target of $37.60, suggesting a potential upside of 84.22%. Given Genmab A/S's higher probable upside, research analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Genmab A/S beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.